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Ageing is accompanied by a marked reduction in natural killer (NK) cell cytotoxicity 
(NKCC) at the single cell level that is thought to contribute to the accumulation of 
senescent cells in aged tissues. Although it is established that decreased killing results 
from reduced perforin secretion in response to co-culture with cancer cells, the 
mechanisms involved in reduced NKCC towards senescent cells remain unknown. 
To investigate reduced NKCC towards senescent cells, we examined the composition 
of the circulating NK cell pool in healthy young (≤35 years) and older (≥65 years) adults, 
focussing primarily on highly differentiated CD57+ NK cells as they show reduced 
function in killing assays. Additionally, we assessed perforin release and mitogen-
activated protein kinase (MAPK) activation in NK cells following NKG2D and NKp30 
receptor ligation given their role in granule polarisation and NKCC towards senescent 
cells. 
Assessment of the composition of the circulating lymphocyte pool revealed a greater 
proportion of NK cells in older adults, with a marked increase in the percentage of 
CD56DIM NK cells and terminally differentiated CD56DIMCD57+ NK cells. Since CD57 
expression is associated with immune cell dysfunction, an increased proportion of 
CD57+ NK cells may contribute to impaired perforin release and NKCC. Whilst we were 
unable to show that NK cells from older adults secreted lower levels of perforin, though 
sample size was low, we found no age-associated difference in P38 MAPK activation 
in NK cells following receptor ligation. Thus, we propose that reduced NKCC with age 
towards senescent cells may be due to defects in the activation of other MAPK 
signalling pathways such as ERK. 
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1.0 INTRODUCTION 
1.1 Population ageing in the UK 
The United Kingdom (UK), like many other countries, is experiencing rapid population 
ageing due to steadily declining birth and early-age mortality rates [1]. Improvements 
in public health and the emergence of preventative care have led to a significant 
increase in average life expectancy and the proportion of older people in society [1,2]. 
Since 1991, the number of individuals aged 65 and over has risen from 9.1 million to 
11.8 million (currently 18% of the UK’s population) [3]. A similar trend, although 
occurring at a much faster rate, has been observed in the ‘oldest old’ group, those 
aged 85 and over, who account for 2.4% of the population [3]. Recent estimates 
suggest that by 2046, the proportion of people aged 65 and over will exceed those 
aged 15 and under by 7%, and comprise 24.7% of the UK’s population [4]. With both 
elderly age groups predicted to increase within the coming decades [3], population 
ageing has become a matter of concern and is expected to have profound implications 
for health and social care provisions due to the increasing prevalence of age-related 
diseases in older adults [2,3].  
1.2 Ageing and immunity 
Physiological ageing is accompanied by remodelling of the immune system that leads 
to immune dysfunction and loss of protective immunity [5]. This phenomenon termed 
immunesenescence is a multifactorial process affecting both arms of the immune 
system that manifests as loss of adaptive immunity and gain of nonspecific innate 
immunity [5-8]. In broad terms, immunesenescence is characterised by increased 
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reactivity, impaired antimicrobial activity, reduced immune surveillance of transformed 
cells and high serum levels of pro-inflammatory cytokines and chemokines. This not 
only reduces the capacity to mount rapid immune responses against foreign 
substances [6], but also creates a low-grade chronic inflammatory state termed 
inflammageing that contributes to the pathogenesis of several diseases including 
atherosclerosis, type II diabetes, sarcopenia, arthritis and Alzheimer’s disease [9-12]. 
As well as an increased susceptibility to infection, immunesenescence results in loss 
of immune memory that reduces the prophylactic efficacy of vaccination with age; this 
is demonstrated by studies that report decreased antibody response post-vaccination 
and reduced vaccine longevity in older adults [13]. Current immune gerontology 
research aims to investigate the impact of immune ageing on health and more recently 
has included a focus on natural killer (NK) cells due to their role in early innate 
responses towards malignant cells, senescent cells and viral-infections. 
1.3 Natural killer (NK) cells 
Compromising approximately 10% of total circulating human lymphocytes, NK cells are 
large granular lymphocytes of the innate immune system that mediate anti-viral and 
anti-tumour responses [14-16]. In humans, NK cells are phenotypically defined as CD3-
CD56+, and can be categorised into two functionally distinct subsets, CD56DIM and 
CD56BRIGHT, based on differential surface expression of CD56 [14,16,17]. CD56DIM NK 
cells are cytotoxic effector cells that constitute the majority (~90%) of NK cells in 
peripheral blood [16-18]. These cells not only express high levels of perforin, but are 
also capable of cytokine and chemokine production following target cell recognition 
[15,19,20]. In contrast, CD56BRIGHT NK cells comprise only ~10% of the circulating NK 
cell pool, but predominate in lymph nodes and tonsils [15,18]. Functionally, CD56BRIGHT 
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NK cells have low cytotoxic potential and lack perforin [21]. Instead, they are 
immunomodulatory and secrete a myriad of cytokines and chemokines such as 
interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) upon stimulation 
[21,22].  
NK cells elicit direct cytotoxicity towards malignant and pathogen-infected cells via two 
mechanisms: granule exocytosis and death receptor ligation. Of the two, granule 
exocytosis is the predominant pathway by which NK cells induce target cell death via 
apoptosis, and involves directed secretion of lytic granules containing perforin and 
granzymes at the immunological synapse that forms at the NK-target cell interface 
[14,23]. After binding and incorporating itself into the target’s plasma membrane [24], 
pore-forming perforin induces a membrane-repair response that results in co-
endocytosis of perforin and granzymes [14,25]. Once inside, perforin induces 
endosomal lysis to facilitate the delivery of endocytosed granzymes into the cytosol 
[14,26]. Human NK cells express five granzymes: granzymes A, B, H, K and M [23,27]. 
Of these serine proteases, granzyme B is the most extensively studied and is primarily 
responsible for the induction of caspase-dependent apoptosis which occurs in one of 
two ways: (1) direct cleavage and activation of effector caspases 3 and 7 to induce 
apoptosis via degradation of DNA repair proteins (2) indirect activation of caspases 3 
and 7 through cleavage of BH3-interacting domain (BID) into truncated BID (tBID), 
which translocates to the mitochondria to trigger cytochrome C release [14,27]. 
Granzyme B can also trigger apoptosis through a caspase-independent mechanism 
that involves direct cleavage of proteins involved in DNA repair and maintenance such 
as poly ADP ribose polymerase (PARP), inhibitor of caspase-activated 
deoxyribonuclease (iCAD) and laminin B [14]. 
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Alongside granule exocytosis, NK cells eliminate target cells through death receptor 
ligation, which involves binding of Fas ligand (FasL) and TNF-related apoptosis-
inducing ligand (TRAIL) upregulated on the surface of activated NK cells to Fas and 
TRAIL receptors respectively on the target cell surface [14]. This leads to formation of 
the death-inducing signalling complex (DISC) and activation of caspases 8 and 10, 
which induce apoptosis directly via caspase 3 activation or indirectly through tBID-
mediated release of cytochrome C from mitochondria [14].  
NK cell activity is governed by the integration of signals received by a complex 
repertoire of germ-line encoded activating and inhibitory surface receptors [16,28,29]. 
Inhibitory receptors, which include killer immunoglobulin-like receptors (KIR) and C-
type lectin family member CD94-NKG2A heterodimer receptor, negatively regulate NK 
cell activity by signalling through cytoplasmic immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) upon interaction with major histocompatibility complex class I 
(MHC I)-expressing cells [16,28,29]. This results in a series of downstream signalling 
events, which disrupt NK cell cytotoxicity (NKCC) to prevent the destruction of healthy 
cells [28,30]. Conversely, most activating receptors (e.g. Fc receptor CD16 (FcγRIII) 
and natural cytotoxicity receptors (NCRs) NKp30, NKp44, NKp46 and NKp80), apart 
from C-type lectin family member NKG2D, lack intrinsic signalling activity and thus 
associate with immunoreceptor tyrosine-based activating motif (ITAM)-bearing adaptor 
proteins to induce NK cell activation and subsequent effector functions (e.g. cytokine 
production, proliferation, migration and target cell lysis) [31]. 
Indeed, co-stimulation of multiple activating receptors following target cell engagement 
is required for NK cell activation [30,32,33]. The combined signals are transmitted 
through several central signalling pathways (e.g. phosphoinositide 3-kinase (PI3K) and 
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janus kinase (JAK)/signal transducer and activator of transcription (STAT)) that 
converge on transcriptional activation of genes crucial for direct cytotoxicity [31,32,34]. 
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine protein 
kinases, consisting of P38, extracellular signal-regulated protein kinase 1/2 (ERK1/2) 
and c-Jun N-terminal kinase (JNK) [35,36], whose activation is required for induction 
of lytic granule polarisation and ultimately NKCC [31,36,37]. Selective inhibition of P38, 
ERK and JNK MAPKs has been shown to reduce NK cell-mediated target cell lysis 
[36,38-40]. It is believed that MAPK signalling is essential for microtubule organising 
centre (MTOC) polarisation, which precedes lytic granule secretion [36,38-40]. Wei et 
al. demonstrated that inhibition of MAPK signalling prevents the delivery of secretory 
lysosomes to the NK cell synaptic cleft, thereby reducing perforin and granzyme B 
secretion [38].  
1.4 Age-associated changes in NK cells 
Like other immune cells, NK cells are subject to various age-related phenotypical and 
functional changes (Tables 1.1 and 1.2). Although ageing is associated with reduced 
NK cell proliferation and production [50-52], numerous studies have shown an 
increased percentage and/or absolute number of NK cells in older adults [51,53,54]. 
This suggests the existence of long-lived CD57+ NK cells, whose frequency increases 
with age [53,54,89]. CD57 expression is a marker of terminal differentiation that is 
commonly associated with senescence in human T cells and mainly affects CD56DIM 
NK cells [89,90]. Despite retaining their cytotoxic potential, CD56DIMCD57+ NK cells 
have a lower proliferative capacity and are less responsive to cytokine stimulation in 
vitro [89,90]. With regards to the composition of the circulating NK cell pool, older adults 
display significantly fewer CD56BRIGHT NK cells and have a higher proportion of 
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CD56DIM NK cells, culminating in an increased CD56DIM:CD56BRIGHT ratio 
[14,54,55,91].  
Alongside redistribution of the NK cell subsets, ageing is associated with changes in 
the expression of activating and inhibitory NK cell receptors, with several studies 
reporting an age-related decrease in CD94, KLRG1 and NKp46 surface expression 
[54,56-58], whereas NKG2D, CD3 and CD16 expression is comparable with age 
[53,54,57,58]. However, the effect of age on NK cell receptor density remains 
controversial due to emerging evidence that the latent herpes virus cytomegalovirus 
(CMV) induces a shift in the NK cell surface phenotype to one that is associated with 
ageing [14,92]. Therefore, the apparent alterations in NK cell receptor expression 
previously observed may be due to a greater prevalence of CMV in the elderly 
population rather than age [92]. 
Whilst the effect of age on death-receptor-mediated apoptosis remains unknown, it is 
well established that ageing is accompanied by a decline in NKCC at the single cell 
level that is associated with decreased lytic activity and impaired granule exocytosis 
[5,14,54,93,94]. In contrast, ADCC, which occurs independently of NKCC and involves 
signalling of the Fc receptor CD16, appears to be unaltered with age [14]. Based on 
these findings, it is of no surprise that NK cell immunesenescence is associated with a 
higher incidence of viral infections and cancers among older adults [14,91,95,96].  
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Table 1.1: Age-associated changes affecting the composition, phenotype and function of 
innate immune cells 









CD38, CD62L & 
CD115 ↓ 
CD11b expression ↑ 
 
TLR1 expression ↓ 
Phagocytosis ↓ 
 
ROS production ↓ 
 
TLR1/2-induced  
IL-6 & TNF-α 
secretion ↓ 
[41-44] 
Neutrophils  Immunosuppressive 
CD16BRIGHTCD62LDIM 
neutrophils ↑ 
Unaltered CD11a & 
CD11b expression 
CD16 expression ↓ 
Chemotaxis ↓ 
Phagocytosis ↓ 
ROS production ↑/↓ 
NETosis ↓ 




Total NK cell 
proportion/frequency ↑ 
 
CD56DIM NK cell 
proportion/frequency ↑ 
 





Gain of CD57 
expression by CD56DIM 
subset 
Comparable NKG2D, 
CD3 & CD16 
expression 
CD94, KLRG1 & 













CD8+CD4- NKT cell 
proportion/frequency ↑ 

















expression on pDCs 
TLR1, 3 & 8 expression 
on mDCs ↓ 
MHC II expression on 
mDCs & pDCs ↓ 
Percentage of 
CD83+CD86+ PBDCs ↑ 
Impaired cytokine 
production  
(IL-6, IL-12, TNF-α,  
IFN-I & IFN-III) 
Migration ↓ 
Phagocytosis ↓ 
Ag presentation ↓ 
 
[63-69] 
Abbreviations: ADCC, antibody-dependent cell cytotoxicity; Ag, antigen; IFN-I, type I interferon; IFN-III, 
type III interferon; IL, interleukin; KLRG1, killer cell lectin-like receptor subfamily G member 1; mDC, 
myeloid DC; MHC II, major histocompatibility complex class II; NET, neutrophil extracellular trap; PBDC, 
peripheral blood DC; pDC, plasmacytoid DC; ROS, reactive oxygen species; TLR, toll-like receptor. 
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Table 1.2: Age-associated changes affecting the composition, phenotype and function 
of adaptive immune cells 
 Composition Phenotype Function References 
T cells Naïve CD4+ & CD8+ T cell 
output ↓  
Memory CD4+ & CD8+ T 
cell frequency ↑ 
Th17 cell differentiation ↑ 
Treg frequency ↑ 
TFR:TFH ratio ↑ 
Loss of CD28 expression 
by CD8+ T cells 
Gain of CD57 expression 
by CD8+ T cells 
TCR repertoire 
diversity ↓ 
CD8+ T cell proliferative 
capacity ↓ 
CD4+ T cell trafficking ↓ 
IFN-γ, TNF-α, 





B cells Plasma cell frequency ↓ 
Naïve B cell percentage ↑ 
Memory B cell frequency ↓ 
Immunosuppressive 
CD19+CD24HiCD38Hi B cell 
percentage/frequency ↓ 
IgM & IgD expression ↓ 
Comparable CD80, CD86 
& CD40 expression on B 
cells 
B cell diversity ↓ 
Defective Ig class 
switching 
Antibody production ↓ 






Abbreviations: Ig, immunoglobulin; TCR, T cell receptor; TFH, T follicular helper cell; TFR, T follicular 
regulatory cell; Th17, T helper cell 17; Treg, regulatory T cell. 
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1.5 Cellular senescence 
In recent years, cellular senescence has gained considerable interest in the field of 
gerontology due to its involvement in normal tissue homeostasis and pathophysiology. 
Cellular senescence is a state of stable irreversible growth arrest that prevents the 
malignant transformation of stressed cells [97,98]. Originally thought to be foremost an 
anti-cancer mechanism, cellular senescence has since been shown to be implicated 
in many physiological processes such as tissue remodelling during embryogenesis and 
wound repair [97,98].  
Senescent cells typically undergo extensive alterations in gene expression, chromatin 
organisation and metabolic programming and are thus characterised by an enlarged, 
flattened morphology, upregulation of senescence-associated ß-galactosidase (SA-ß-
gal), persistent DNA damage foci and apoptosis resistance [97,99-101]. Cellular 
senescence can be induced in a number of mitotic cell types including fibroblasts and 
epithelial cells in response to severe genomic or epigenomic stress caused by 
telomere erosion, mitochondrial dysfunction, oxidative stress, irreparable DNA 
damage, oncogenic overexpression and aberrant mitogenic signalling 
[97,99,100,102,103]. Entry into senescence is mediated and maintained through 
activation of the p53/p21CIP1 and p16INK4a/retinoblastoma protein (pRB) tumour 
suppressor pathways following persistent DNA damage response (DDR) signalling 
(Figure 1.1) [97,103,104]. Ultimately, stabilisation of p53 and upregulation of p16INK4a 
lead to activation of master regulator pRB, which prevents progression from G1 to S 
phase of the cell cycle by inhibiting E2F-dependent transcription [102,103].  
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Figure 1.1: Molecular pathways regulating cellular senescence and the SASP 
Cellular senescence is induced by severe genomic or epigenomic damage that leads 
to activation of the DDR and the INK4/ARF locus. Persistent DDR signalling causes 
stabilisation of p53, which induces expression of cyclin-dependent kinase (CDK) 
inhibitor p21. Inhibition of cyclinE-CDK2 by p21 results in dephosphorylation of pRB 
and repression of E2F-responsive genes, thereby preventing cell cycle progression. 
Concurrently, 16INK4a expression is induced in response to persistent DDR signalling 
through increased ROS signalling and activation of P38 MAPK and protein kinase C 
(PKC), and activation of the INK4/ARK locus upon disruption of the Polycomb 
repressive complex (PRC). Ultimately, p16INK4a selectively inhibits cyclin D-CDK4/6, 
promoting pRB-mediated cell cycle arrest. In some forms of oncogene-induced 
senescence, growth arrest can be reinforced by the senescence-associated 
secretory phenotype (SASP), whose activity is primarily regulated by transcription 
factors nuclear factor-kappa B (NK-κB) and CCAAT-enhancer-binding protein-beta 
(C/EBP-ß), and p53. Figure adapted from review articles by Herranz and Gil [102], 
and Campisi and Roberts [103]. 
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Despite losing their proliferative capacity upon senescence [103], senescent cells 
remain metabolically active and acquire a pro-inflammatory phenotype termed the 
senescence-associated secretory phenotype (SASP) [102,105]. As part of the SASP, 
senescent cells secrete a myriad of pro-inflammatory cytokines, chemokines, growth 
factors and extracellular matrix (ECM) components which have widespread paracrine 
and autocrine activities in tissues [105-109]. These effects can be either beneficial or 
deleterious depending on the biological context [108]. Beneficial aspects of the SASP 
appear to confer a potent tumour suppressive response driven by senescence 
reinforcement and immune surveillance [110-115]. Moreover, transient exposure to the 
SASP is known to direct tissue repair, limit fibrosis and induce cellular plasticity and 
“stemness” in neighbouring cells to promote tissue regeneration following acute injury 
[116-118]. In contrast, the SASP can have tumour-promoting activities in tissues, 
stimulating the proliferation and metastasis of transformed cells [108,119]. For 
example, increased secretion of SASP-derived factors IL-6 and IL-8 by senescent 
fibroblasts has been shown to induce epithelial-mesenchymal transition and enhanced 
invasion in nonaggressive carcinoma cells [108]. Moreover, upregulation of pro-
angiogenic factors such as vascular endothelial growth factor (VEGF) by the senescent 
cell secretome stimulates tumour vascularisation in mice and humans in vitro [120]. 
This apparent paradox confers dual functionality of the SASP in the context of 
physiology and pathology where a localised, time-limited SASP is beneficial for tumour 
clearance and tissue repair [121]. Whereas chronic exposure to the SASP is 
deleterious, creating a pro-inflammatory environment that disrupts tissue integrity and 
favours cancer evolution [108,121].  
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Recently, it has been postulated that senescent cells contribute to ageing and the 
development of age-related diseases. Evidence has shown that senescent cells 
accumulate in aged tissues and at sites of pathology despite being less abundant in 
healthy young individuals [107,122]. It is this increased presence and propagation of 
the SASP that are believed to drive pathogenicity in tissues. For instance, cognitive 
impairment and reduced neurogenesis in Alzheimer’s and Parkinson’s disease have 
been linked to an increased abundance of senescent glial cells and secretion of pro-
inflammatory SASP-derived factors such as IL-6 in brain tissue [123,124]. Similarly, 
SASP-mediated ECM remodelling has been shown to drive atheroma formation and 
plaque instability in atherosclerosis [125,126]. These associative data are supported 
by two consecutive studies in BubR1 progeroid mice, in which selective deletion of 
p16Ink4a-positive senescent cells in adipose, eye and skeletal muscle delayed the onset 
and attenuated the progression of already established age-related disorders, namely 
sarcopenia and cataracts [127]. Furthermore, drug-induced clearance of senescent 
cells extended lifespan in mice, delayed tumorigenesis and attenuated age-related 
deterioration of several organs including the kidney, heart and fat in this transgenic 
mouse model [128]. Such findings have prompted research into the use of senolytic 
drugs to reduce the senescent cell burden [129,130]. However, there are many 
unknowns and potential drawbacks to utilising these therapies due to the lack of human 
studies [98,131].  
1.6 NK cell cytotoxicity towards senescent cells 
Although there is causal evidence that lingering senescent cells are involved in the 
pathogenesis of age-related diseases, the mechanisms by which these cells 
accumulate have not been elucidated. Recent findings suggest that senescent cell 
 Page | 13 
clearance may be impaired with age, contributing to their persistence in tissues. 
Several immune cell types including macrophages, neutrophils and CD8+ T cells are 
known to eliminate senescent cells [115]. However, NK cells are thought to be the 
major innate cell involved in the removal of senescent cells, which they directly 
recognise through activating receptor NKG2D, which binds its respective ligands MHC 
I chain related-proteins A and B (MICA/B) and UL16-binding proteins 1-6 (ULBP1-6) 
expressed on senescent cells [132]. However, in order to NKCC following target cell 
engagement, co-stimulation of multiple activating receptors such as NKp30 which 
recognises MHC I molecules is required. Since upregulation of decoy receptor 2 (Dcr2) 
by senescent cells prevents death receptor ligation by competitively binding NK cell 
death receptor ligands (i.e. FasL and TRAIL) [133], the predominant mechanism by 
which NK cells eliminate senescent cells is contact-dependent granule exocytosis 
(Figure 1.2) [14,134].  
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Figure 1.2: NK cell-mediated killing of senescent cells via granule exocytosis 
NK cells recognise transformed cells through activating receptor NKG2D, which 
binds stress-inducible glycoproteins (e.g. MICA/B) expressed on the senescent cell 
surface. Due to upregulation of Dcr2 on senescent cells, NK cell-mediated killing is 
biased towards granule exocytosis, which involves rapid expulsion of secretory 
granule contents perforin and granzymes into the immunological synapse. Upon 
degranulation, pore-forming perforin binds to and disrupts the target cell membrane, 
triggering co-endocytosis of perforin and granzymes. Through perforin-mediated 
endosomal lysis, granzyme B is delivered into the cytosol where it induces 
senescent cell apoptosis via various caspase-dependent and -independent 
mechanisms. 
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Despite being renowned for their ability to mediate direct cytotoxicity against 
transformed cells [135], NK cells show a marked reduction in killing ability with age that 
is thought to contribute to the accumulation of senescent cells. The reason for this is 
likely to be multifactorial. Pereira and colleagues proposed that senescent cells evade 
immune surveillance by upregulating surface expression of non-classical MHC 
molecule human leukocyte antigen-E (HLA-E), thus contributing to their persistence in 
tissues [136]. The group showed that by blocking interactions between HLA-E and 
inhibitory receptor NKG2A, NK and CD8+ T cell-mediated surveillance of senescent 
cells was significantly improved in vitro [136]. Marked alterations in the phenotype and 
function of NK cells with age may also contribute to incomplete elimination of 
senescent cells. Despite effectively recognising and binding to tumour targets, NK cells 
from older adults exhibit an age-associated decline in NKCC that is indicative of a post-
binding defect in NK cell activation and/or degranulation [5,53,93,94]. Groups that have 
investigated the effect of age on the expression of key NK cell receptors and lytic 
effector molecules needed for direct cytotoxicity have reported contradictory results 
regarding activating receptors NKG2D and NKp30 and perforin and granzyme B 
expression [14,53,56,137,138]. Despite these conflicting observations, Hazeldine et al. 
found no age-associated difference in perforin expression, but did report impaired 
perforin secretion and polarisation at the immunological synapse by NK cells from old 
subjects following co-culture with the K562 cancer cell line [54]. Interestingly, a 
reduction in perforin secretion has been shown to promote senescent cell 
accumulation and age-related disorders in perforin knockout mice [139], suggesting 
perforin is indispensable for NKCC-mediated cytotoxicity towards senescent cells. 
Importantly, M. Tariq has also found reduced NKCC towards senescent fibroblasts with 
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age [unpublished, personal communication], and this has formed the basis of this 
thesis. 
Although it is well-documented that ageing is accompanied by a marked reduction in 
NKCC-mediated granule exocytosis [14,53], the mechanisms responsible remain 
unknown. However, there is mounting evidence to suggest that this intrinsic defect may 
be the result of aberrant intracellular signalling, a theme commonly associated with 
immune cell dysfunction in older adults [5,34,48]. Supporting this assumption is the 
work conducted by our laboratory which showed comparable amounts of perforin 
released by NK cells from young and old adults treated with phorbol 12-myristate 13-
acetate (PMA) and ionomycin [unpublished findings by J. Hazeldine], compounds that 
bypass cell surface receptors to activate PKC directly and induce effector functions 
such as NK cell degranulation [5,14]. Similarly, Mariani et al. previously showed that 
NK cells from older adults have a lower capacity to generate second messenger 
inositol triphosphate (IP3) following K562 stimulation due to an age-associated delay 
in phosphatidyl-inositol bisphosphate (PIP2) hydrolysis [140]. This age-related 
decrease in calcium-mobilising IP3 may interfere with downstream signalling events, 
such as phosphorylation of MAPKs or activation of PKC, involved in degranulation. In 
conclusion, these observations reinforce the theory that impaired perforin secretion 
may be due to compromised intracellular signalling required for perforin mobilisation at 
the immunological synapse [14]. 
As previously mentioned, the activation of MAPKs is crucial for lytic granule 
polarisation during granule exocytosis, and ultimately NKCC [31,36-40]. Whilst no 
study to date has investigated the impact of age on MAPK signalling in NK cells, Lanna 
et al. proposed constitutive activation of MAPKs by sestrins drives T cell 
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immunesenescence [141]. Interestingly, this group showed an increased frequency of 
sestrin-dependent MAPK activation complexes (sMACs) in stressed and aged T cells, 
which simultaneously coordinate autophosphorylation of P38, ERK and JNK MAPKs 
[141]. Disruption of the sMACs restored several antigen-specific functional responses 
in vitro, suggesting sestrins have pro-ageing activities in T lymphocytes [141]. More 
recently, our own data has found constitutive activation of ERK1/2 in resting NK cells 
from older adults and that this is associated with increased sestrin 2 expression 
[unpublished observations by M. Tariq]. Based on these findings, we propose that 
constitutive activation of MAPKs may also be implicated in NK cell 
immunesenescence, contributing to disrupted MAPK signalling and reduced NKCC-
mediated perforin secretion with age. 
1.7 Hypothesis and aims 
Physiological ageing is accompanied by a decline in NKCC driven in part by reduced 
secretion and polarisation of perforin at the immune synapse. This age-associated 
impairment in granule exocytosis may contribute to incomplete senescent cell 
clearance with age. Given that MAPK signalling is crucial for NKCC and lytic granule 
polarisation, we hypothesised that following NKG2D and NKp30 receptor ligation, 
involved in the recognition of senescent cells, NK cells from older adults would exhibit 
aberrant activation of P38 and ERK1/2 MAPK signalling compared with younger 
subjects that would result in an age-associated decrease in perforin release. To 
address this hypothesis, the following aims were set: 
• Determine the impact of ageing on the composition of the circulating 
lymphocyte pool; 
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• Determine the maturity, CD57+ cell percentage, of the circulating NK cell pool; 
• Investigate the effect of age on perforin release by NK cells following NKG2D 
and NKp30 receptor ligation; 
• Investigate the effect of age on P38 and ERK1/2 activation in NK cells at rest 
and following receptor ligation of the activating receptors NKG2D and NKp30.  
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2.0 MATERIALS AND METHODS 
2.1 Reagents and equipment 
2.1.1 Reagents and chemicals 
• Medium for PBMC isolation: RPMI-1640 media supplemented with 2% (v/v) L-
glutamine-penicillin-streptomycin (GPS; Sigma-Aldrich, Missouri, USA) 
• Ficoll-Paque™ Plus (GE Healthcare, Buckinghamshire, UK) 
• autoMACS® Running buffer: 0.5% (w/v) bovine serum albumin (BSA), 2mM 
ethylenediaminetetraacetic acid (EDTA), phosphate-buffered saline (PBS), 
0.09% (v/v) azide (Miltenyi Biotec, Bergisch Gladbach, Germany) 
• Complete medium for NK cell resuspension: RPMI-1640 media supplemented 
with 10% fetal calf serum (FCS) and 2% GPS (Sigma-Aldrich, Missouri, USA) 
• 50 μl of Fix & Perm® Medium A (Life Technologies, Carlsbad, CA) 
• 25 nm PMA (Sigma-Aldrich, Missouri, USA) 
• 1.6% (w/v) paraformaldehyde (PFA; Sigma-Aldrich, Missouri, USA) 
• Carbonate-bicarbonate buffer (Sigma-Aldrich, Missouri, USA) 
• 10% (v/v) heat-inactivated FCS (HIFCS; Sigma-Aldrich, Missouri, USA) 
• 2x sodium dodecyl sulphate (SDS) sample buffer: 4% (v/v) SDS, 0.1M 
dithiothreitol (DTT), 20% (w/v) glycerol, 0.0625M Tris-HCL, 0.004% (w/v) 
bromophenol blue and double distilled water (ddH2O) (Sigma-Aldrich, Missouri, 
USA) 
• BSA (Fisher Scientific, New Hampshire, USA) 
• TBST: 1x Tris buffered saline (TBS) (pH 7.5) containing 0.1% (v/v) Tween-20 
(Fisher Scientific, New Hampshire, USA) 
• Enhanced chemoluminescence (ECL) substrates (GE Healthcare, 
Buckinghamshire, UK)  
• Mild stripping buffer: 1.5% (w/v) glycine, 0.1% (w/v) SDS, 1% (v/v) Tween-20 
and ddH2O (pH 2)  
2.1.2 Antibodies 
• 200 μg/ml Pacific Blue™-conjugated mouse anti-human CD3 antibody (Clone: 
UCHT1; BioLegend®, San Diego, CA) 
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• 50 μg/ml PE-conjugated monoclonal mouse anti-human CD56 antibody 
(Clone: AF12-7H3; Miltenyi Biotec, Bergisch Gladbach, Germany)  
• 50 μg/ml FITC-conjugated mouse anti-human CD57 antibody (Clone: HCD577; 
BioLegend®, San Diego, CA) 
• 2.5 μg/ml APC anti-ERK1/2 phosphospecific mouse antibody (Clone: 6B8B69; 
BioLegend®, San Diego, CA)  
• 2.5 μg/ml APC isotype mouse IgG2α κ antibody (Clone: MOP; BioLegend®, 
San Diego, CA) 
• 5 μg/ml NKG2D agonistic monoclonal antibody (Clone: 149810; R&D Systems, 
Minneapolis, MN)  
• 5 μg/ml NKp30 agonistic monoclonal antibody (Clone: 210847; R&D Systems, 
Minneapolis, MN)  
• Phospho-P38 rabbit monoclonal antibody (Cell Signalling Technology, 
Massachusetts, USA) 
• Phospho-p44/42 MAPK (ERK1/2) rabbit monoclonal antibody (Cell Signalling 
Technology, Massachusetts, USA)  
• HRP conjugated-anti-rabbit IgG antibody (GE Healthcare, Buckinghamshire, 
UK)  
• P38 rabbit monoclonal antibody (Cell Signalling Technology, Massachusetts, 
USA) 
• p44/42 MAPK (ERK1/2) rabbit monoclonal antibody (Cell Signalling 
Technology, Massachusetts, USA) 
2.1.3 Equipment and software 
• NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
• LS columns and a QuadroMACS Separator (Miltenyi Biotec, Bergisch 
Gladbach, Germany) 
• CyAnADP cytometer (Dako Ltd, Cambridge, UK)  
• Summit v4.3 software (Beckman Coulter, California, USA) 
• Commercial perforin (PRF1) human in vitro ELISA kit (Abcam, Cambridge, UK) 
• Spectrophotometer (BioTek, Vermont, USA)  
• Gen5 software (BioTek, Vermont, USA) 
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• GraphPad Prism® software (GraphPad Software Inc., California, USA) 
• Polyvinylidene difluoride (PVDF) membranes (Bio-Rad, California, USA)  
• ChemiDoc technology (Bio-Rad, California, USA)  
• ImageLab software (Bio-Rad, California, USA) 
• ImageJ software (National Institutes of Health, Maryland, USA)  
2.2 Participants and blood sampling 
This study was approved by the University of Birmingham Research Ethics Committee 
(ref REN 14-1342). A total of 16 healthy young (mean age 28 years, range 18-35 years, 
6 female, 10 male) and 23 healthy old (mean age 74 years, range 65-82 years, 15 
female, 8 male) volunteers were recruited into this study. Individuals taking any 
medication known to influence function were excluded from this study. Prior to blood 
sampling, written consent was obtained from all volunteers, who at the time were free 
from infection. Approximately 20-30 ml of Venous blood was collected into heparinised 
vacutainers (BD Biosciences, Oxford, UK) by qualified healthcare professionals under 
sterile conditions using a standard venepuncture technique.  
2.3 Immune cell isolation  
2.3.1 Peripheral blood mononuclear cell (PBMC) isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood 
samples using Ficoll-Paque density gradient centrifugation. To begin, heparinised 
blood was diluted at a 1:1 ratio with RPMI-1640 media supplemented with 2% (v/v) 
GPS. To establish a Ficoll-Paque density gradient, 10-15 ml of blood was gently 
layered on top of 6 ml of Ficoll-Paque™ Plus. Gradients were centrifuged at 400 x g 
for 30 minutes at 22°C with no break. Post-spin, PBMCs, which resided at the plasma-
Ficoll-Paque interface, were transferred into 25 ml universals containing autoMACS® 
Running buffer. Cells were washed twice with autoMACS® Running buffer at 300 x g 
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for 10 minutes at 22°C. Supernatants were discarded and cells re-suspended in 10 ml 
of autoMACS® Running buffer, after which PBMC numbers were determined using a 
haemocytometer.  
2.3.2 NK cell isolation 
NK cells were separated from PBMC suspensions via negative selection using a NK 
cell isolation kit and MACS® technology (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Freshly isolated PBMCs were spun at 300 x g for 10 minutes at 22°C, after 
which supernatants were discarded and cells were re-suspended in 40 μl of 
autoMACS® Running buffer per 107 total cells. PBMCs were incubated with 10 μl of 
human NK cell biotin-antibody cocktail (Miltenyi Biotec, Bergisch Gladbach, Germany) 
per 107 total cells for 10 minutes at 4°C with occasional mixing. Post incubation, 30 μl 
of autoMACS® Running buffer per 107 total cells was added to the mixture, which was 
incubated with 20 μl of NK cell MicroBeads cocktail (Miltenyi Biotec, Bergisch 
Gladbach, Germany) per 107 total cells for 10 minutes at 4°C with occasional mixing. 
Cell suspensions were made up to 500 μl with autoMACS® Running buffer in 
preparation for magnetic separation. 
To separate non-magnetically labelled NK cells from the magnetically labelled cell 
fraction, LS columns were placed in the magnetic field of a QuadroMACS Separator 
and washed with 3 ml of autoMACS® Running buffer. PBMC suspensions were passed 
through the LS columns, followed by 3 ml of autoMACS® Running buffer to flush any 
remaining non-magnetic NK cells. Purified NK cells were collected and centrifuged at 
300 x g for 10 minutes at 22°C. Supernatants were discarded and cells were re-
suspended in RPMI-1640 media supplemented with 10% FCS and 2% GPS (hereafter 
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referred to as complete medium). NK cell numbers were determined using a 
haemocytometer.  
2.4 Immunostaining 
2.4.1 NK cell phenotyping 
Freshly isolated PBMCs were stained with CD3, CD56 and CD57 antibodies to analyse 
the composition of the NK cell pool in both young and old volunteers. In brief, 250,000 
PBMCs were plated into wells of a 96-well round bottom-plate (BD Falcon™, New 
Jersey, USA), which was spun at 250 x g for 5 minutes at 4°C. Following centrifugation, 
supernatants were discarded and cells re-suspended in 92 μl of PBS prior to 
immunostaining. Cells were stained with 1 μl of Pacific Blue™-conjugated mouse anti-
human CD3 antibody,  2 μl of PE-conjugated monoclonal mouse anti-human CD56 
antibody and 5 μl of FITC-conjugated mouse anti-human CD57 antibody for 15 minutes 
on ice in the dark. Post incubation, cells were washed with 100 μl of PBS at 250 x g 
for 5 minutes at 4°C. Cells were fixed with 50 μl of Fix & Perm® Medium A for 20 
minutes in the dark at room temperature (RT), after which PBMCs were washed with 
100 μl of PBS at 250 x g for 5 minutes at 4°C. Subsequent pellets were re-suspended 
in 300 μl of PBS and placed in 5ml polypropylene round-bottom tubes (BD Falcon™) 
for flow cytometric analysis on a CyAnADP cytometer using Summit v4.3 software.  
To determine lymphocyte proportions, 10,000 lymphocytes were gated based on a 
forward scatter (FS)/side scatter (SS) properties and the percentage of cells displaying 
a CD3+, CD3+CD56+, CD3-CD56+, CD3-CD56+CD57- and CD3-CD56+CD57+ surface 
phenotype recorded (Figure 2.1). 
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Figure 2.1: Gating strategy for NK cell phenotyping from PBMCs 
(A) 10,000 cells were gated using a FS/SS flow cytometry plot to analyse the composition 
of the circulating lymphocyte pool. (B) NK cells were identified by a CD3-CD56+ surface 
phenotype examined on a Violet 1 Log/PE log comp flow cytometry plot. (C) Based on 
differential expression of CD56, NK cells were further categorised into two distinct 
subpopulations: CD56DIM and CD56BRIGHT. (D) Afterwards, NK cell subsets and total NK 
cells were assessed for CD57 surface expression, which allowed identification of four 
distinct NK cell subgroups: CD56DIMCD57-, CD56DIMCD57+, CD56BRIGHTCD57- and 
CD56BRIGHTCD57+. 
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2.4.2 Measurement of ERK activation by flow cytometry 
To analyse activation of the ERK1/2 signalling pathway in response to stimulation with 
PMA, NK cells (2 x 106ml) were treated with 25nM PMA for 5 minutes (37°C, 5% CO2). 
Untreated NK cells were used to determine basal ERK1/2 expression. Post stimulation, 
NK cells were washed with 300 μl of ice cold PBS at 250 x g for 5 minutes at 4°C, after 
which supernatants were discarded and cells fixed with 300 μl of 1.6% (w/v) PFA for 
30 minutes in the dark at RT. Following fixation, NK cells were washed with 300 μl of 
ice cold PBS at 250 x g for 5 minutes at 4°C, and subsequent pellets permeabilised 
with 300 μl of ice cold methanol for 20 minutes in the dark at RT. Cells were washed 
with 2 ml of ice cold PBS at 250 x g for 5 minutes at 4°C and re-suspended in 95 or 
97.5 μl of ice cold PBS in preparation for intracellular staining. NK cells were stained 
with 2.5 μl of APC anti-ERK1/2 phosphospecific mouse antibody or 5 ul of APC isotype 
mouse IgG2α κ antibody for 30 minutes in the dark at 4°C. Afterwards, cells were 
washed with 500 μl of ice cold PBS at 250 x g for 5 minutes at 4°C; supernatants were 
discarded and NK cells re-suspended in 300 μl of ice cold PBS for flow cytometric 
analysis on a CyAnADP cytometer using Summit v4.3 software. 10,000 NK cells were 
counted and the percentage of APC positive NK cells recorded along with the 
corresponding median fluorescence intensity (MFI) value. 
2.5 Antibody stimulation of NK cells 
As described by Hazeldine et al., 96-well flat-bottomed Enzyme-Linked 
Immunosorbent Assay (ELISA) Nunc plates (BD Falcon™) were coated with 100 μl of 
mouse monoclonal antibodies targeted against activating receptors NKG2D and 
NKp30 diluted from stock with carbonate-bicarbonate buffer [54]. After overnight 
incubation at 4°C, plates were washed 3X with 200 μl of PBS and blocked with 100 μl 
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of 10% (v/v) HIFCS/PBS for 30 minutes at RT. Post incubation, the blocking solution 
was decanted and plates washed 3X with 200 μl of PBS in preparation for NK cell 
stimulation. 
150,000 freshly isolated NK cells were added to the wells and samples incubated with 
the NKG2D and NKp30 agonistic antibodies for 2, 5, 10, 30, 60, 90, 120 and 180 
minutes (37°C, 5% CO2).  
To prepare cell lysates for Western blotting, 20 μl of hot 2x SDS sample buffer was 
added to the wells and lysates transferred to 0.5 ml Eppendorf’s. Samples were boiled 
at 100°C for 10 minutes and stored at -20°C. Untreated NK cells served as basal 
controls. 
For measurement of perforin secretion, receptor-stimulated NK cells were transferred 
to 0.5 ml Eppendorf’s and centrifuged at 1500 x g for 2 minutes at 4°C. Post spin, cell-
free supernatants were collected and stored at -80 until use. 
2.6 Measurement of perforin release by stimulated NK cells 
Perforin concentrations were determined using a commercial perforin (PRF1) human 
in vitro ELISA kit. Briefly, 80 μl of complete medium was added to thawed samples and 
100 μl aliquots dispensed into wells of a microtiter plate pre-coated with a monoclonal 
antibody specific for perforin. Following incubation for 1 hour at RT, wells were 
aspirated and washed 3X with 1x wash buffer (diluted 200-fold from 200x wash buffer 
concentrate with ddH2O). Post wash, 50 μl of 1x biotinylated anti-perforin (diluted from 
stock with biotinylated antibody diluent) was added into wells and the plate incubated 
for 1 hour at RT. Afterwards, the liquid was decanted and wells washed 3X with 1x 
wash buffer prior to incubation with 100 μl of 1x streptavidin-HRP solution (streptavidin-
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HRP concentrate diluted with HRP-diluent) for 30 minutes at RT. Following liquid 
aspiration, wells were washed 3X with 1x wash buffer and incubated with 100 μl of 
chromogen TMB substrate solution for approximately 5 minutes in the dark at RT, after 
which 100 μl of stop reagent was dispensed into wells and the absorbance read on a 
spectrophotometer with a primary wavelength of 450 nm and a reference wavelength 
of 630 nm using Gen5 software. Perforin concentrations were determined using a 
standard curve that was created using values obtained from standards of known 
perforin concentrations via GraphPad Prism® software. 
2.7 Assessment of MAPK signalling in receptor-stimulated NK cells 
by Western blotting 
Frozen NK cell lysates were placed on a heating block for 8 minutes at 100°C and 
separated on 10% SDS-polyacrylamide gels for 90 minutes at 150V with a current of 
35 amps. Proteins were transferred onto PVDF membranes for 90 minutes at 100V 
with a limit of 0.45 amps, after which membranes were blocked with 5% (w/v) BSA in 
1x Tris buffered saline (TBS) (diluted 10-fold from 10x TBS (pH 7.5)) containing 0.1% 
(v/v) Tween-20; hereafter referred to as TBST) for 1 hour at RT. Blots were probed 
with rabbit monoclonal antibodies targeted against phospho-P38 or phospho-p44/42 
MAPK (ERK1/2) (both diluted 1:1000 with TBST containing 2.5% (w/v) BSA) overnight 
on a shaker at 4°C. The following day, primary antibodies were removed and blots 
washed 3X for 15 minutes with TBST at RT before being probed with HRP conjugated-
anti-rabbit IgG antibody (diluted 1:4000 in TBST; GE Healthcare) for 1 hour at RT on 
a shaker. Post incubation, blots were washed 3X for 10 minutes with TBST, after which 
protein levels were determined by ECL using ChemiDoc technology  and ImageLab 
software. 
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Total loading controls were prepared to confirm equal amounts of protein expression 
across samples. In brief, blots were stripped with mild stripping buffer for 20 minutes 
at RT with some agitation to remove bound antibodies for subsequent primary antibody 
probing. Blots were washed twice with PBS for 10 minutes on a shaker at RT, followed 
by two more washes with TBST for 5 minutes on a shaker at RT. After the final wash, 
blots were washed for 15 minutes with TBST and blocked with 5% (w/v) BSA in TBST 
for 1 hour at RT. Afterwards, blots were probed with rabbit monoclonal antibodies 
targeted against P38 and p44/42 MAPK (ERK1/2) (diluted 1:1000 with 1x TBS 
containing 2.5% (w/v) BSA). The following day, blots were washed 3X for 15 minutes 
with TBST and probed with anti-rabbit IgG antibody conjugated with HRP for 1 hour at 
RT on a shaker. Blots were washed 3X for 10 minutes with TBST and protein levels 
were determined by ECL using ChemiDoc technology and ImageLab software. 
Densitometry analysis was performed using ImageJ software to quantify protein 
expression. 
2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism® software. Data distribution 
was checked using a Kolmogorov-Smirnov test. For normally distributed data either a 
paired or unpaired student t-test was used, whereas a Wilcoxon-matched pairs signed 
rank test or a Mann Whitney U test was applied for non-normally distributed data. To 
assess differences between the means of P38 phosphorylation in unstimulated and 
receptor-stimulated NK cells, a repeated measures analysis of variance (ANOVA) was 
performed in addition to Dunnett’s post hoc test. Statistical significance was accepted 
at P ≤ 0.05.  
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3.0 RESULTS 
3.1 The effect of age on the composition of the lymphocyte pool 
Immunostaining and flow cytometric analysis of PBMCs isolated from healthy young 
and old adults were used to determine the effect of age on the composition of the 
circulating lymphocyte pool. Differences in lymphocyte proportions were observed 
between the two groups with older adults displaying a significantly lower proportion of 
CD3+CD56- T lymphocytes compared to young adults (P = 0.0218) (Figure 3.1A). 
Conversely, no age-related difference in the proportion of circulating NKT cells was 
found due to marked variation in the percentage CD3+CD56+ of NKT cells between 
older participants (P = 0.4100) (Figure 3.1B). Analysis of NK cells revealed a greater 
percentage of CD3-CD56+NK cells in the lymphocyte pool of older adults, which rose 
from 10.66% in younger adults to 15.77% in elders (P = 0.0008) (Figure 3.1C).  
3.2 The effect of age on the percentage of NK cell subsets 
NK cells can be categorised as CD56DIM or CD56BRIGHT based on differential surface 
expression of CD56 [14]. When analysed according to this criterion, we found that older 
adults had a significantly higher proportion of CD3-CD56DIM NK cells (14.97%) in their 
lymphocyte pool compared to young adult controls (9.57%) (P = 0.0004) (Figure 3.2A). 
However, no age-related difference in the percentage of CD3-CD56BRIGHT NK cells was 
observed (P = 0.2241) (Figure 3.2B).  
  










Figure 3.1: Age-related changes in the composition of the lymphocyte pool 
(A-C) Comparison of the circulating percentage of T cells (A), NKT cells (B) and NK 
cells (C) between young and old adults. Values represent mean ± standard error of 
the mean (SEM) of 10 young and 13 old donors (A-B) and 15 young and 18 old 
donors (C) with differences between the groups assessed using unpaired student t-
tests and Mann Whitney U tests. Data are combined with previous unpublished work 
by L. Rimmer: young (n=5) and old (n=5) participants. 











Figure 3.2: Effect of age on the distribution of NK cell subsets 
(A-B) Comparison of the percentage of circulating CD56DIM (A) and CD56BRIGHT (B) 
NK cells between young and old donors taken as a proportion of total circulating 
lymphocytes. Values represent mean ± SEM of 15 young and 18 old donors. 
Differences between the two groups were assessed by an unpaired student t-test 
(A) and a Mann Whitney U test (B). Data are combined with previous unpublished 
work by L. Rimmer: young (n=5) and old (n=5) participants. 
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3.3 The effect of age on NK cell maturity 
One facet of immunesenescence is the accumulation of terminally differentiated 
immune cells, which is thought to drive immune dysfunction and may contribute to 
functional deterioration in NK cells, including reduced NKCC with age [52,142]. Thus, 
NK cells were assessed based on differential surface expression of CD57, a marker of 
cell maturity. We found that older adults expressed a significantly higher proportion of 
CD57+ NK cells (55.73%) than their younger counterparts (38.46%) (P = 0.0017) 
(Figure 3.3A). When looking at CD57 expression in specific NK cell subsets, the 
percentage of CD56DIMCD57+ NK cells was significantly higher in older adults (P = 
0.0232) (Figure 3.3B). However, we did not observe an age-related difference in the 
proportion of CD56BRIGHTCD57+ NK cells (P = 0.3434) (Figure 3.3C).  
3.4 Perforin release by receptor-stimulated human NK cells 
To determine the impact of age on perforin release by NK cells in response to 
recognition of senescent cells, perforin concentrations were compared between NK 
cells isolated from young and old donors following ligation of activating receptors 
NKG2D and NKp30. A time course of 2 and 3 hours was used as previous work by our 
laboratory showed perforin secretion is highest at these time points [unpublished work 
by M. Tariq; 54]. Unexpectedly, no differential effect for age was observed as NK cells 
from older adults released similar amounts of perforin at both time points compared 
with younger subjects (P = 0.1467 for the 2 hour time point) (Figure 3.4A and 3.4B).  
  








Figure 3.3: Effect of age on NK cell maturity 
(A-C) Comparison of the percentage of CD57+ total NK cells (A), CD56DIMCD57+ 
NK cells (B) and CD56BRIGHTCD57+ NK cells (C) between young and old adults. 
Values represent mean ± SEM of 15 young and 18 old donors (A) and 10 young 
and 13 old donors (B-C). Differences between the two groups were assessed by 
unpaired student t-tests and Mann Whitney U tests. (A) Data are combined with 
previous unpublished work by L. Rimmer: young (n=5) and old (n=5) participants. 










Figure 3.4: Effect of age on perforin secretion by receptor-stimulated NK cells  
(A-B) Comparison of perforin secretion by receptor-stimulated NK cells between 
young and old subjects after 2 (A) and 3 (B) hours of NKG2D and NKp30 activating 
receptor ligation. Data are mean ± SEM of 10 young and 3 old donors (A) and 10 
young and 2 old donors (B). Differences between the two groups were assessed 
by an unpaired student t-test (A). 
 Page | 35 
3.5 P38 and ERK1/2 MAPK signalling in resting and PMA-treated NK 
cells  
Constitutive MAPK activation has been shown previously to occur in NK cells from old 
donors [unpublished work by M. Tariq]. Since this age-related difference in P38 and 
ERK MAPK signalling has been shown to drive immunesenescence in aged T cells 
[141], constitutive activation of P38 and ERK MAPKs may also be implicated in 
reduced NKCC with age. To determine whether there are age-related differences in 
basal P38 and ERK1/2 MAPK signalling, P38 and ERK1/2 phosphorylation in resting 
human NK cells and those stimulated with 25nM of PMA were assessed by Western 
blotting and flow cytometry. We observed no increase in P38 signalling following PMA 
stimulation in both age cohorts (P = 0.1982 for young adults; P = 0.1141 for older 
adults) (Figure 3.5A-B). Additionally, there was no age-related difference in P38 
phosphorylation in unstimulated NK cells (P = 0.3147) (Figure 3.5C).  
Using flow cytometric analysis, we observed a significant increase in the percentage 
of NK cells that stained positive for phosphorylated ERK following PMA stimulation (P 
< 0.0001 for young adults; P = 0.0014 for older adults) (Figure 3.6A), which 
corresponded to a higher staining intensity of phosphorylated ERK (P = 0.0008 for 
young subjects) (Figure 3.6B). Nonetheless, no age-associated difference in either the 
percentage of NK cells positive for phosphorylated ERK or the staining intensity for this 
protein was found in resting (P = 0.3485 for % ERK+ NK cells; P = 0.3762 for pERK 
MFI) and PMA-treated NK cells (P = 0.3762 for % ERK+ NK cells; P = 0.5048 for pERK 
MFI) (Figure 3.6A and Figure 3.6B). Similarly, no statistical change was witnessed 
when upregulation of phosphorylated ERK in response to PMA stimulation was 
compared between the two groups (Figure 3.6C and Figure 3.6D). Analysis by Western 
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blotting revealed that PMA stimulation rapidly induced ERK1/2 signalling in NK cells 
from young and old donors (Figures 3.7A and 3.7B). However, there was no age-
related difference in the expression of phosphorylated ERK1/2 in resting (P = 0.0865) 
or PMA-stimulated NK cells (P = 0.1331) (Figure 3.7C). This pathway is therefore intact 
with age in response to PMA.  









Figure 3.5: Activation of P38 in resting NK cells 
(A-C) Comparison of phosphorylated P38 expression in resting and PMA-stimulated NK 
cells between young and old donors. (A-B) Representative blots showing the 
phosphorylation kinetics of P38 in resting and PMA-stimulated NK cells from young (A) 
and old (B) donors. (C) Densitometry analysis of phosphorylated P38 expression. Data 
are mean ± SEM of 4 young and 6 old donors. For statistical analysis, paired t-tests, 
Mann Whitney U tests and Wilcoxon matched-pairs signed rank tests were used. 






Figure 3.6: Phosphorylated ERK staining in resting NK cells  
(A-D) Intracellular staining of phosphorylated ERK1/2 in resting and PMA-
stimulated NK cells isolated from 4 young and 6 old donors. (A) Percentage of NK 
cells positive for phosphorylated ERK. (B) Phosphorylated ERK staining intensity 
(MFI). Fold increase above baseline in the percentage of pERK positive NK cells 
(C) and MFI values (D). Data are mean ± SEM with differences between groups 
assessed by paired and unpaired student t-tests, a Wilcoxon matched-pairs signed 
rank test and Mann Whitney U tests. 







Figure 3.7: Activation of ERK1/2 in resting NK cells 
(A-C) Freshly isolated NK cells were treated with 25 nM PMA for 5 minutes, after 
which phosphorylated ERK1/2 expression was assessed by Western blot analysis 
with Total ERK1/2 serving as a loading control. (A-B) Representative blots depicting 
the phosphorylation kinetics of ERK1/2 in resting and PMA-stimulated NK cells from 
young (A) and old (B) donors. (C) Densitometry analysis of phosphorylated ERK1/2 
protein expression. Data are mean ± SEM of 3 young and 6 old donors. For 
statistical analysis, paired t-tests, Wilcoxon matched-pairs signed rank tests and 
Mann Whitney tests were used. 
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3.6 P38 and ERK1/2 MAPK signalling in receptor-stimulated NK 
cells 
Given that MAPK signalling has been shown to be crucial for NKCC and granule 
exocytosis and was positive in response to PMA at least for ERK activation [31,36,37], 
we sought to determine whether ageing is associated with aberrant P38 activation in 
response to receptor ligation. To address this, human NK cells were incubated with 
agonistic antibodies targeted against NKG2D and NKp30 activating receptors over a 
90-minute period, after which P38 and ERK1/2 protein phosphorylation was assessed 
by Western blotting. Unexpectedly, P38 phosphorylation decreased over the 
stimulation period and was significantly lower 90 minutes after receptor cross-linking 
in young adults (P ≤ 0.01) (Figure 3.8), no difference in P38 phosphorylation was seen 
in receptor-stimulated NK cells from old donors (Figure 3.9). 
NKG2D and NKp30 receptor ligation also did not rapidly induce ERK1/2 activation in 
NK cells isolated from young adults as indicated by low protein phosphorylation. 
Instead, stimulated NK cells expressed comparable amounts of phosphorylated 
ERK1/2 at each time point to that in unstimulated NK cells (Figure 3.10). Time did not 
allow for the study to be repeated in old adults. 
  





Figure 3.8: P38 activation in NK cells isolated from young adults following 
NKG2D-NKp30 receptor ligation 
Phosphorylated P38 expression in human NK cells stimulated with 5 μg/ml of 
agonistic antibodies against NKG2D and NKp30 receptors over a 90-minute time 
course. Top panel shows a representative blot of 4 independent experiments for 
P38 stimulations. Bottom panel represents densitometry analysis of P38 MAPK 
activation. Data are mean ± SEM (n=4) with differences from each time point 
compared with 0 minute controls. For statistical analysis, a repeated measures 
ANOVA test was performed followed by Dunnett’s post hoc test. ** indicates p ≤ 
0.01. 






Figure 3.9: P38 activation in NK cells isolated from older adults following 
NKG2D-NKp30 receptor ligation 
Human NK cells were crosslinked with agonistic antibodies targeted against 
NKG2D and NKp30 activating receptors for the indicated time points. Cell extracts 
were prepared and Western blotting analysis performed to determine 
phosphorylated P38 and Total P38 protein expression. Top panel: Representative 
Western blot, depicting P38 phosphorylation. Bottom panel: Represents 
densitometry analysis of P38 MAPK activation. Data are mean ± SEM (n=2). 






Figure 3.10: ERK1/2 activation in NK cells isolated from young adults 
following NKG2D-NKp30 receptor ligation 
Phosphorylated ERK1/2 expression in human NK cells stimulated with 5 μg/ml of 
agonistic antibodies against NKG2D and NKp30 receptors over a 90-minute time 
course. Top panel shows a representative blot of 4 independent experiments for 
ERK1/2 stimulations. Bottom panel represents densitometry analysis of ERK1/2 
MAPK activation. Data are mean ± SEM with differences from each time point 
compared with 0 minute controls. For statistical analysis, a repeated measures 
ANOVA was performed along with Dunnett’s post hoc test. 
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4.0 DISCUSSION 
Cellular senescence is a central component of ageing that has been shown to 
contribute to the pathology of numerous age-related diseases [107,122-126]. Normally, 
senescent cells are recognised and eliminated by various immune cell types, including 
NK cells [115]; however, physiological ageing is accompanied by remodelling of the 
immune system, termed immunesenescence, that affects both innate and adaptive 
immunity and leads to immune incompetence [5,7,8]. Decreased killing is a well-
documented feature of NK cell immunesenescence that may contribute to the age-
related accumulation of senescent cells across tissues [54,134]. Studies that have 
investigated the effect of age on NK cell killing have reported an age-associated 
decline in NKCC at the single level that is associated with reduced lytic activity and 
impaired granule exocytosis [53,93,94]. Underlying this impairment appears to be an 
age-related decrease in perforin secretion by NK cells that has been attributed to 
reduced lytic granule polarisation towards the immunological synapse [54]. 
Nevertheless, the mechanism(s) responsible for this defect have yet to be unearthed; 
therefore, the aim of this thesis was to elucidate the causes underlying compromised 
NKCC with age.  
Here we show that ageing is accompanied by marked alterations in the composition of 
peripheral NK cells. Specifically, we observed an increased proportion of 
CD56DIMCD57+ NK cells with age that caused a shift in the maturity status of the 
circulating NK cell pool towards terminal differentiation. Given that acquisition of CD57 
expression is associated with functional deterioration in other immune cells 
[89,90,143], we propose that an increased in CD56DIMCD57+ NK cells may contribute 
to reduced NKCC with age. We assessed perforin in response to NKG2D and NKp30 
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receptor ligation but found no reduced perforin release with age. Analysis of 
intracellular signalling pathways in activated NK cells revealed no age-associated 
difference in P38 or ERK MAPK phosphorylation in response to PMA, but we also 
found no activation of P38 in response to receptor ligation, though ERK was activated 
in young donor NK cells. We did not investigate ERK activation in response to receptor 
ligation in old donor NK cells. Thus, defects in the activation of MAPKs such as 
ERK1/2, which plays a prominent role in lytic granule polarisation [37,38,40], may 
underlie the age-related decline in NKCC and further research with higher sample 
numbers is required. 
4.1 NK cell phenotype and percentage 
In agreement with previous studies [51,53,54], our results showed ageing to be 
accompanied by marked alterations in the composition of the circulating lymphocyte 
pool. Compared with young subjects, older adults presented with a lower proportion of 
CD3+ lymphocytes but a substantially higher percentage of CD3-CD56+ NK cells. This 
increased percentage suggests the existence of long-lived NK cells in the periphery 
[53,54,89]. Interestingly, the proportion of CD3+CD56+ NKT cells was unaltered with 
age, which contrasts with earlier observations that show a significant decrease in the 
proportion of NKT cells in elderly individuals [59-62]. Possible reasons for this 
discrepancy are differences in gender and the use of specific NKT cell markers. For 
instance, Molling et al. demonstrated that in both young and old age groups, males 
have a lower proportion of NKT cells compared with females and that the age-
associated decrease in NKT cells is more prominent in males than in females [62]. 
Contrary to earlier reports [59-62], our study did not age- and gender-match donors or 
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specifically stain for NKT cell markers, which may explain why we did not witness an 
age-related difference in the proportion of NKT cells. 
Based on differential surface expression of CD56, human NK cells can be categorised 
into two functionally distinct subgroups, CD56DIM and CD56BRIGHT NK cells, whose 
distribution changes with age [14]. In contrast with other reports [54,55,91], our results 
did not reveal a difference in the proportion of CD56BRIGHT NK cells between young and 
old adults. However, we did observe an age-associated increase in the CD56DIM NK 
cell percentage that was consistent with earlier studies that noted a profound increase 
in the percentage of CD56DIM NK cells in elderly individuals [54,55,91]. Whilst 
contributing to the age-associated increase in the circulating NK cell proportion, 
CD56DIM NK cell abundance may serve to counterbalance the age-associated decline 
in NKCC observed at the single cell level [54]. Originally thought to be solely 
responsible for direct cytotoxicity, CD56DIM NK cells, like CD56BRIGHT NK cells, are a 
major source of pro-inflammatory cytokines and chemokines that have various 
immunomodulatory effects in tissues [19,20,54,144]. Given that this subgroup rapidly 
produces greater amounts of pro-inflammatory modulators compared with CD56BRIGHT 
NK cells following target cell recognition [20], an increased proportion of CD56DIM NK 
cells in the periphery may therefore amplify ongoing inflammatory responses through 
the recruitment and overstimulation of immune effector cells [54], thereby contributing 
to immunesenescence and inflammageing.  
In addition to redistribution of NK cell subpopulations, ageing is accompanied by a shift 
in the maturity status of the circulating NK cell pool towards terminal differentiation. 
Our findings revealed older adults possess a greater proportion of NK cells that stain 
positive for CD57 in comparison with younger subjects. This observation was reflected 
 Page | 47 
by an age-associated increase in the proportion of CD56DIMCD57+ NK cells, whereas 
the percentage of CD56BRIGHTCD57+ NK cells was not affected by age. As a marker of 
cell maturity, CD57 expression on NK cells increases with age and predominantly 
affects CD56DIM NK cells [54,89,90]. Importantly, CD57 is commonly associated with 
senescence in human T cells [89,90,143], and may therefore contribute to NK cell 
immunesenescence in older adults [54]. Mature CD56DIMCD57+ NK cells display 
distinct phenotypical and functional differences in comparison with immature CD56DIM 
NK cells; these include decreased responsiveness to cytokine stimulation and poor 
proliferative capacity that correlates with an increased inhibitory KIR proportion 
[89,90,144]. Although CD56DIMCD57+ NK cells exhibit greater lytic activity following 
interaction with IgG-coated targets and become more frequent with age [89], older 
adults display similar levels of ADCC in comparison with young individuals, indicating 
ADCC may be impaired at the single cell level [54]. Similarly, acquisition of CD57 
expression by CD56DIM NK cells may also explain why an age-related increase in the 
proportion of CD56DIM NK cells does not translate into enhanced NKCC. 
4.2 Perforin release in response to receptor ligation 
As previously mentioned, ageing is accompanied by a decline in NKCC at the single 
cell level that is characterised by impaired granule exocytosis [54,93,94]. Hazeldine et 
al. has also shown NKCC towards senescent cells to be reduced with age 
(unpublished). This author showed that despite comparable conjugate formation, NK 
cells from older adults exhibit reduced lytic activity towards tumour cells and impaired 
perforin secretion as a consequence of reduced secretory granule polarisation towards 
the immunological synapse [54]. Although this work looked at NK cell responses 
towards tumour cells, NK cells utilise the same pathway used to remove tumour cells 
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to also eliminate senescent cells. Importantly, NK cells recognise senescent cells via 
interactions between the NKG2D activating receptor and MICA/B ligands expressed 
on the senescent cell surface. Thus, to further investigate the mechanisms underlying 
reduced NKCC with age, we stimulated NK cells isolated from young and old donors 
with NKG2D and NKp30 receptor agonists for 2 and 3 hours, after which perforin 
concentrations were determined by ELISA. However, given the small sample size, we 
were unable to show a significant difference in perforin release by receptor-stimulated 
NK cells. Instead, our data suggested the concentration of perforin was comparable 
between young and old subjects after 2 and 3 hours of receptor ligation, which 
contrasts with previous data [54]. A possible explanation for these opposing 
observations is differences in NK cell stimulation. Whereas we only used two 
antibodies to stimulate two activating receptor types (i.e. NKG2D and NKp30), 
Hazeldine et al. used whole tumour cells to induce perforin secretion; thus, in this 
setting, there are more receptor-ligand interactions, which may result in a more 
prominent activating stimulus for the NK cell. Additionally, perforin secretion was not 
assessed in resting NK cells; therefore it may be that these antibodies are not agonistic 
or active in this model. Consequently, future work should aim to repeat this experiment 
using whole senescent cells, a larger sample size and resting NK cells as controls to 
study the effect of age on NKCC towards senescent cells. 
4.3 MAPK signalling 
MAPK activation is required for MTOC polarisation and lytic granule secretion during 
granule exocytosis, and ultimately NKCC [36-40]. Whilst no study to date has 
investigated the impact of age on MAPK signalling in NK cells, Lanna et al. showed 
constitutive activation of P38, ERK and JNK to be associated with increased sMAC 
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formation in aged T cells [141]. Although sestrins are stress-sensing proteins known 
for their anti-ageing properties, this group found that sestrins contribute to T cell ageing 
by promoting constitutive MAPK signalling and T cell dysfunction [141]. More recently, 
preliminary data from our group had found constitutive activation of ERK1/2 in resting 
NK cells from older adults, and that this was also associated with increased sestrin 
expression [unpublished work by M. Tariq]. Since there is compelling evidence that 
suggests NK cells from older adults exhibit reduced granule polarisation [54], we 
investigated the effect of age on P38 and ERK1/2 MAPK signalling in resting and 
receptor-stimulated NK cells. In contrast with previous unpublished work by M. Tariq, 
our data showed resting NK cells from young and older adults displayed constitutive 
P38 activity, but not ERK1/2. However, P38 phosphorylation did not differ between 
young and old donors, suggesting that there is no age-associated difference in MAPK 
activation in resting NK cells. Therefore, we concluded that the mechanisms driving 
functional deterioration in aged NK cells may differ to that observed in aged and 
stressed T cells. 
With regards to MAPK activation in receptor-stimulated NK cells, NK cells from young 
adults were less responsive to receptor ligation compared with older subjects. In young 
subjects, receptor-stimulated NK cells exhibited significantly lower P38 activity in 
comparison with unstimulated NK cells at 90 minutes, which was unexpected. 
Conversely, P38 signalling did not differ between unstimulated and receptor-stimulated 
NK cells from older adults. Thus, we were unable to determine an age-associated 
difference in P38 activation in NK cells. Instead, we concluded that other MAPK 
signalling pathways such as ERK may be implicated in reduced NKCC with age. 
Assessment of ERK1/2 signalling in young adults revealed increased phosphorylated 
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ERK1/2 in receptor-stimulated NK cells, but this was only n=2. No studies were 
performed in old adult cells.  
4.4 Future work 
A proposed follow up study would be to determine whether there is an age-associated 
difference in ERK activation in receptor-stimulated NK cells given the significance of 
ERK in MTOC polarisation and perforin release. If an age-associated difference in ERK 
activation is found, it would be interesting to study PKC delta (PKCδ) activation in NK 
cells upon receptor ligation, since PKCδ (an upstream regulator of ERK) has been 
shown to be play a major role in lytic granule polarisation in CD8+ T cells [145]. For 
example, Ma et al. previously demonstrated that upon stimulation, diacylglycerol 
(DAG) rapidly phosphorylates PKCδ, which localises to lytic granules and polarises 
them towards the immunological synapse for release [146]. 
Additionally, it would be interesting to compare perforin secretion between CD57- and 
CD57+ NK cells to determine whether an increased percentage of CD56DIMCD57+ NK 
cells drives reduced NKCC with age. It is also important to repeat the perforin release 
studies, increasing the numbers for the old NK cell group with the inclusion of controls. 
Given that we only examined the impact of age on the proportion of circulating NK 
cells, it would also be interesting to determine whether age also affects the frequency 
of NK cells.  
4.5 Conclusion 
In summary, this study has shown that ageing is accompanied by marked alterations 
in the composition of the circulating NK cell pool, namely an increased proportion of 
CD3-CD56+ NK cells attributed to accumulation of long-lived CD56DIMCD57+ NK cells 
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in the periphery. We propose that this shift in the maturity status of the NK cell pool 
may contribute to reduced NKCC with age given that terminal differentiation is 
associated with senescence in T cells. We were unable to show reduced perforin 
secretion by receptor-stimulated NK cells with age, and did not find ageing to be 
associated with constitutive activation of P38 or ERK1/2 in resting NK cells. NK cells 
from older adults exhibited a similar level of ERK signalling to that of young subjects in 
response to PMA. Moreover, stimulating human NK cells with NKG2D and NKp30 
receptor agonists rapidly induced ERK MAPK signalling in young adults, but did not 
increase P38 signalling in both age groups. Taken together, these results suggest that 
reduced perforin secretion is not affected by P38 signalling with age, but may be the 
result of defects in the activation of MAPK signalling pathways such as ERK in 
CD56DIMCD57+ NK cells. Therefore, future work should look to determine the role of 
ERK signalling in the age-related decline in perforin release by NK cells.  
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